The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
LRRK2 Cohort Consortium Resource Request, 2013Alpha-synuclein and Other Biomarkers in Biological Samples of LRRK2 Parkinson’s Disease
Objective/Rationale:
Cerebrospinal fluid (CSF) biomarkers of Alzheimer’s pathology have been investigated in Parkinson’s disease (PD), and abnormal CSF protein levels (tau and phosphorylated tau, beta... -
Clinical Intervention Awards, 2007Serotonin and Sleep Disordered Breathing in Parkinson Disease
Objective/Rationale:
Sleep related problems are a major cause of impairment in Parkinson's disease. Recent studies indicate a high incidence of a disabling sleep disorder – sleep disordered breathing... -
Computational Science, 2017Analyzing Data from the Parkinson’s Progression Markers Initiative to Identify Subtypes of Parkinson’s Disease
Study Rationale:
Parkinson's disease (PD) presents and progresses variably, so no two people with Parkinson's have the same disease. The diversity of PD clinical manifestations makes the disease more... -
Access to Data & Biospecimens, 2017Klotho and Parkinson’s disease
Study Rationale:
Genetic studies have identified a powerful “aging suppressor gene”, Klotho, that may play a role in delaying age-related declines in cellular and tissue functioning...
-
Biomarker Development, 2015Biomarker and DNA Samples Collection Add-on Study to the Phase III Trial of Isradipine
Study Rationale:
Isradipine, an FDA-approved agent for treatment of high blood pressure, was shown to be have neuroprotective benefit in models of Parkinson’s disease (PD). A recently completed Phase... -
Therapeutic Pipeline Program, 2015Inhibitors of Alpha-synuclein Oligomers for the Treatment of Parkinson’s Disease
Study Rationale:
The alpha-synuclein protein forms oligomers (protein clumps) that cause toxicity in the brains of individuals with Parkinson’s disease (PD). We have developed methods that can measure...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.